Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study developed expert consensus guidelines on using low-dose oral and topical minoxidil for pattern hair loss around hair transplant surgery, recommending specific doses, monitoring practices, and timing of use for both male and female patients.

This study developed consensus guidelines for using low-dose oral and topical minoxidil in patients undergoing hair transplant surgery for pattern hair loss, recommending dosing adjustments, monitoring protocols, and timing for post-surgery application.

The authors concluded that while finasteride 1 mg affects prostate-related pathways, evidence is insufficient to prove clinical benefits for prostate outcomes compared to the established effectiveness of finasteride 5 mg.

This study found that among women with female pattern hair loss, low-dose oral minoxidil improved hair loss severity and quality of life scores despite 71.6% experiencing mild to moderate unwanted hair growth, which most patients did not consider a reason to discontinue treatment.

This study established consensus-based guidelines for using low-dose oral and topical minoxidil in managing pattern hair loss for patients undergoing hair transplant surgery, recommending specific dosages, monitoring procedures, and timing for initiation post-surgery.

This study suggests that side effects of low-dose oral minoxidil for hair loss are infrequent and demographics did not influence this risk, but dosage relative to body weight may affect adverse event incidence.

In this study, women with female pattern hair loss using low-dose oral minoxidil reported significant improvements in hair loss severity and quality of life, with most experiencing mild or moderate unwanted hair growth but continuing treatment regardless.

This study found that women with female pattern hair loss experienced improvements in hair loss severity and quality of life from low-dose oral minoxidil use, despite a common side effect of unwanted hair growth, which most did not consider a reason to stop treatment.

This study suggests that low-dose oral minoxidil is safe and effective in treating COVID-19 associated telogen effluvium, as indicated by a significant decrease in hair-shedding scores over follow-up visits.

In this retrospective study, researchers reported that low-dose oral minoxidil significantly improved hair density in 60 patients with androgenetic alopecia or telogen effluvium over 4-8 months, as detected through standardized AI-powered imaging.

In this report, two pediatric patients with short anagen syndrome, a condition causing difficulty in growing long scalp hair, showed positive responses to low‐dose oral minoxidil treatment.

In a proof-of-concept study at Xiangya Hospital, the researchers observed that combining tofacitinib with low-dose interleukin-2 helped maintain remission in refractory alopecia areata patients, with three out of four maintaining complete remission for 11–20 months post-treatment and no adverse events reported.

This study found that low-dose oral minoxidil (≤5 mg/day) effectively increased hair number and diameter in men and women with androgenetic alopecia, and was generally well-tolerated with mostly mild adverse effects, although serious complications were rare and associated mainly with pre-existing heart conditions.

Low-dose oral minoxidil does not significantly affect blood pressure in patients with hair loss and hypertension.

Low-dose oral minoxidil may be a promising alternative to topical minoxidil for hair loss.

In this study, low concentrations of DMSO were found to decrease androgen receptor expression and inhibit the migration of prostate cancer cells, suggesting potential as an anticancer therapy.

This review highlights that while low-dose oral minoxidil appears well-tolerated in cancer patients post-chemotherapy, its use during active chemotherapy has shown potential benefits but remains under investigation, with preclinical studies suggesting a protective effect against chemotherapy-induced alopecia.

In this study on C3H/HeJ-engrafted mice, a single injection of BMD-1141 significantly increased anagen hair follicle counts and enhanced hair regrowth compared to daily high-dose ruxolitinib, suggesting it stimulates hair growth by influencing the hair cycle rather than altering immune response.

Low-dose oral minoxidil is safe for the heart in the short term for hair loss patients.

This study highlights the diverse prescribing and monitoring practices for low-dose oral minoxidil among dermatologists in the UK and Ireland, used widely for various hair loss conditions both as monotherapy and adjunctive therapy.

Low-dose Ritlecitinib may help children with stubborn Alopecia Areata.

This article discusses the rising use of low-dose oral minoxidil for androgenetic alopecia and mentions common side effects like hypertrichosis, but provides no new clinical findings.

This retrospective study in a tertiary hair clinic concluded that routine monitoring of heart rate, weight, liver, and kidney function is not necessary for asymptomatic patients with normal baseline values undergoing low-dose oral minoxidil treatment, although monitoring is advised for those with preexisting renal impairment.

In this study, injectable microdepots containing rapamycin and poly(lactic-co-glycolic acid) were developed and demonstrated to effectively promote hair regrowth in mice by sustaining drug release and inducing anagen phase transition in hair follicles through modulating autophagy and the Wnt/β-catenin pathway.

Low-dose oral minoxidil doesn't affect blood pressure in patients taking blood pressure meds.

This study reviewed adverse events associated with low-dose oral minoxidil for treating alopecia, finding hypertrichosis and fluid retention as common, typically manageable side effects without needing treatment discontinuation.

This study found that low-dose oral minoxidil effectively increased hair count over 24 weeks with mild reductions in blood pressure and minimal adverse effects among participants, suggesting its potential as a safe treatment for hair loss.

Combining PRP with topical minoxidil is most effective for hair growth in androgenetic alopecia.

Spironolactone helps prevent swelling caused by minoxidil in women with hair loss.

The study explores the potential effectiveness of low-dose oral minoxidil in treating short anagen hair syndrome, suggesting it may be a viable treatment option despite the condition often resolving spontaneously with puberty.